Anaptysbio (ANAB) Change in Accured Expenses (2016 - 2026)

Anaptysbio has reported Change in Accured Expenses for 11 years, with the latest figure at -$17.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 25.86% year-over-year to -$17.8 million; the trailing twelve-month figure through Mar 2026 stood at -$81.1 million (down 53.92% YoY), and the FY2025 full-year result was -$87.3 million, down 158.08% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$17.8 million, up from -$22.4 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.5 million in Q1 2023, with the low at -$40.0 million in Q4 2024.
• Historically, Change in Accured Expenses has averaged -$7.0 million across 5 years, with a median of -$1.5 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 8706.67% — and 2024, when it sank 2573.36%.
• Anaptysbio's Change in Accured Expenses stood at $4.8 million in 2022, then slumped by 131.0% to -$1.5 million in 2023, then slumped by 2573.36% to -$40.0 million in 2024, then jumped by 44.04% to -$22.4 million in 2025, then rose by 20.49% to -$17.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$17.8 million (Q1 2026), -$22.4 million (Q4 2025), and -$18.6 million (Q3 2025), per Business Quant data.